A systematic review of the effect of alendronate on bone mineral density in men

Journal of Clinical Densitometry

Volumn 8, Issue 1, 2005, Pages 7-13

  Sawka, Anna M ^a,b   Thabane, Lehana ^a,b   Papaioannou, Alexandra ^a   Gafni, Amiram ^a   Hanley, David A ^c   Adachi, Jonathan D ^a,b,d  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d NONE   (Canada)

Author keywords

Alendronate; Bisphosphonate; Bone Density; Males

Indexed keywords

ALENDRONIC ACID; CALCIUM; PLACEBO; VITAMIN D;

ADOLESCENT; ADULT; BONE DENSITY; BONE MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR NECK; FRACTURE; HIP; HUMAN; LUMBAR SPINE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 15344342332     PISSN: 10946950     EISSN: None     Source Type: Journal    
DOI: 10.1385/JCD:8:1:007     Document Type: Article

References (33)

1. Crandall C. 2000 Gender differences in osteoporosis treatment: a review of clinical research. J Gender Specific Med 3(8):42-46.
2. Riggs BL, Melton LJ III. 1995 The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 17(5 Suppl): 505S-511S.
3. Tenenhouse A, Joseph L, Kreiger N, et al. 2000 Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA reference standard: the Canadian Multicenter Osteoporosis Study (CaMos). Osteoporos Int 11(10):897-904.
4. Jackson SA, Tenenhouse A, Robertson L. 2000 Vertebral fracture definition from population-based data: preliminary results from the Canadian Multicenter Osteoporosis Study (CaMos). Osteoporos Int 11(8):680-687.
5. Looker AC, Orwoll ES, Johnston CC Jr, et al. 1997 Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 12(11):1761-1768.
6. Lips P. 1997 Epidemiology and predictors of fractures associated with osteoporosis. Am J Med 103(2A):3S-8S.
7. Gullberg B, Duppe H, Nilsson B, et al. 1993 Incidence of hip fractures in Malmo, Sweden (1950-1991). Bone 14 (Suppl 1): S23-S29.
8. Kenny A, Taxel P. 2000 Osteoporosis in older men. Clin Cornerstone 2(6):45-51.
9. Cree M, Soskolne CL, Belseck E, et al. 2000 Mortality and institutionalization following hip fracture. J Am Geriatr Soc 48(3):283-288.
10. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. 1999 Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353(9156): 878-882.
11. Trombetti A, Herrmann F, Hoffmeyer P, Schurch MA, Bonjour JP, Rizzoli R. 2002 Survival and potential years of life lost after hip fracture in men and age-matched women. Osteoporos Int 13(9):731-737.
12. Diamond TH, Thornley SW, Sekel R, Smerdely P. 1997 Hip fracture in elderly men: prognostic factors and outcomes. Med J Aust 167(8):412-415.
13. Kellie SE, Brody JA. 1990 Sex-specific and race-specific hip fracture rates. Am J Public Health 80(3):326-328.
14. Hasserius R, Karlsson MK, Nilsson BE, Redlund-Johnell I, Johnell O. 2003 Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study. Osteoporos Int 14(1):61-68.
15. Adachi JD, Ioannidis G, Berger C, et al. 2001 The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int 12(11):903-908.
16. Adachi JD, Ioannidis G, Pickard L, et al. 2003 The association between osteoporotic fractures and health-related quality of life as measured by the Health Utilities Index in the Canadian Multicenter Osteoporosis Study (CaMos). Osteoporos Int 14(11):895-904.
17. Ray NF, Chan JK, Thamer M, Melton LJ III. 1997 Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 12(1):24-35.
18. Kanis JA, Johnell O, Oden A, De Laet C, Mellstrom D. 2001 Diagnosis of osteoporosis and fracture threshold in men. Calcif Tissue Int 69(4):218-221.
19. Melton LJ III, Atkinson EJ, O'Connor MK, O'Fallon WM, Riggs BL. 1998 Bone density and fracture risk in men. J Bone Miner Res 13(12):1915-1923.
20. Cranney A, Wells G, Willan A, et al. 2002 Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23(4):508-516.
21. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. 2002 Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23(4):570-578.
22. DerSimonian R, Laird N. 1986 Meta-analysis in clinical trials. Con Clin Trials 7:177-188.
23. Cranney A, Tugwell P, Wells G, Guyatt G. 2002 Meta-analyses of therapies for postmenopausal osteoporosis. I. Systematic reviews of randomized trials in osteoporosis: introduction and methodology. Endocr Rev 23(4):496-507.
24. Ringe JD, Faber H, Dorst A. 2001 Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab 86(11):5252-5255.
25. Ringe JD, Orwoll E, Daifotis A, Lombardi A. 2002 Treatment of male osteoporosis: recent advances with alendronate. Osteoporos Int 13(3):195-199.
26. Orwoll E, Ettinger M, Weiss S, et al. 2000 Alendronate for the treatment of osteoporosis in men. N Engl J Med 343(9):604-610.
27. Gonnelli S, Cepollaro C, Montagnani A, et al. 2003 Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study. Calcif Tissue Int 73(2): 133-139.
28. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. 2003 The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349(13):1216-1226.
29. van der Poest CE, van Engeland M, Ader H, Roos JC, Patka P, Lips P. 2002 Alendronate in the prevention of bone loss after a fracture of the lower leg. J Bone Miner Res 17(12): 2247-2255.
30. Kushida K, Shiraki M, Nakamura I, et al. 2002 The efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis: a randomized, double-blind, active-controlled, double-dummy trial. Curr Ther Res Clin E 63(9):606-620.
31. Ho YV, Frauman AG, Thomson W, Seeman E. 2000 Effects of alendronate on bone density in men with primary and secondary osteoporosis. Osteoporos Int 11(2):98-101.
32. Ringe JD, Dorst A, Faber H, Ibach K. 2004 Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int 24(2):110-113.
33. Lunt M, Felsenberg D, Adams J, et al. 1997 Population-based geographic variations in DXA bone density in Europe: the EVOS Study. European Vertebral Osteoporosis. Osteoporos Int 7(3):175-189.